+50.9% · 90d
$52.95
+0.06 (+0.11%)
After-Hours $52.95(+0.00)
News
(1)April 2026
Terns Pharmaceuticals, Inc. — SC 14D9 Filing
TERNTerns Pharmaceuticals, Inc.
# 🧾 What This Document Is This is a **Schedule 14D-9**, a formal "solicitation/recommendation statement." Think of it as Terns' official letter to its shareholders. Its job? To explain the company's board of directors' recommendation on a **major event**—in this case, an acquisition offer from ph
Read summaryView on SEC EDGAR
Peers in Biotechnology
VRTX#1
Vertex Pharmaceuticals Incorporated
$113.64B+0.64%
REGN#2
Regeneron Pharmaceuticals, Inc.
$78.80B-0.99%
ARGX#3
argenx SE
$49.22B+1.97%
ALNY#4
Alnylam Pharmaceuticals, Inc.
$42.61B-1.82%
ONC#5
BeOne Medicines AG
$34.75B+0.39%
INSM#6
Insmed Incorporated
$34.45B-0.37%
RPRX#7
Royalty Pharma plc
$27.86B+0.84%
BNTX#8
BioNTech SE
$23.26B-0.11%
ROIV#9
Roivant Sciences Ltd.
$20.38B+1.10%
MRNA#10
Moderna, Inc.
$20.34B-1.57%